Unlocking the potential with the use of check-point inhibitor immunotherapies in metastatic prostate cancer
We have read the article published in this journal (December 2018) titled “Immunotherapy: a glimmer of hope for metastatic prostate cancer” with great interest (1). We wish to add on to the content of the article. The article being a comprehensive and well written review article focuses upon all aspects of immunotherapies in relation to prostate cancer—ranging from the use of anti-tumor vaccines, to the use of checkpoint inhibitors. We are of the opinion that future progress in the treatment of metastatic prostate cancer could be found in the combination of immune checkpoint inhibitor therapies with other modalities including chemotherapy, radiotherapy and hormonal therapy.